
    
      OUTLINE:

      Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Treatment repeats
      every 3 weeks for up to 18 cycles in the absence of disease progression or unacceptable
      toxicity.

      After completion of study treatment, patients are followed up for 30 days and then up to 5
      years.
    
  